Table 2.
Details of all patients with bleeding outcomes
| Sex/age (y) | Type of bleeding outcome | DOAC dose | Inappropriate DOAC prescription | C-trough level (ng/mL) | C-peak level (ng/mL) | History of bleeding | HAS-BLED score |
|---|---|---|---|---|---|---|---|
| Major bleeding | |||||||
| M/86 | Gastrointestinal | Apixaban 2.5 mg/BID | No | 337 | NA | No | 3 |
| M/93 | Retroperitoneal (fatal) | Apixaban 2.5 mg/BID | No | 218 | 369 | No | 4 |
| F/86 | Hemoglobin fall | Apixaban 2.5 mg/BID | Yes | 206 | 415 | No | 4 |
| F/77 | Hemoglobin fall | Apixaban 2.5 mg/BID | Yes | 175 | 349 | No | 3 |
| F/70 | Intracranial | Apixaban 2.5 mg/BID | Yes | 164 | 155 | Yes | 5 |
| M/88 | Gastrointestinal | Apixaban 2.5 mg/BID | Yes | 106 | 115 | Yes | 4 |
| M/88 | Gastrointestinal | Apixaban 2.5 mg/BID | Yes | 87 | 221 | No | 2 |
| F/76 | Hemoglobin fall | Apixaban 2.5 mg/BID | Yes | 47 | 213 | No | 2 |
| M/90 | Hemoglobin fall | Apixaban 2.5 mg/BID | Yes | 44 | 79 | No | 4 |
| M/73 | Hemoglobin fall | Apixaban 5 mg/BID | No | 235 | 308 | No | 3 |
| M/81 | Intracranial | Apixaban 5 mg/BID | Yes | 120 | 187 | No | 3 |
| M/83 | Gastrointestinal | Apixaban 5 mg/BID | No | 109 | 102 | No | 3 |
| M/76 | Gastrointestinal | Apixaban 5 mg/BID | No | 55 | NA | No | 2 |
| M/84 | Gastrointestinal | Dabigatran 110 mg/BID | No | 143 | 299 | No | 2 |
| F/84 | Gastrointestinal | Edoxaban 30 mg | No | 169 | 312 | No | 4 |
| F/83 | Intracranial (Fatal) | Edoxaban 30 mg | No | 147 | NA | No | 3 |
| F/83 | Hemoglobin fall | Edoxaban 30 mg | No | 87 | 196 | No | 3 |
| F/83 | Intracranial | Edoxaban 30 mg | No | 23 | 207 | No | 5 |
| M/69 | Gastrointestinal | Edoxaban 30 mg | Yes | 10 | 85 | No | 2 |
| F/83 | Hematuria in K (Fatal) | Edoxaban 30 mg | No | 8 | 159 | No | 4 |
| M/85 | Gastrointestinal | Edoxaban 60 mg | No | 65 | NA | No | 1 |
| M/74 | Intraocular | Edoxaban 60 mg | No | 30 | 381 | No | 1 |
| M/65 | Intracranial | Edoxaban 60 mg | No | 25 | 254 | No | 1 |
| M/80 | Hemoglobin fall | Edoxaban 60 mg | No | 25 | 23 | No | 2 |
| M/80 | Intraarticular | Edoxaban 60 mg | No | 24 | 422 | Yes | 3 |
| M/78 | Gastrointestinal | Rivaroxaban 15 mg | No | 57 | NA | No | 3 |
| M/87 | Hemoglobin fall | Rivaroxaban 15 mg | No | 21 | 231 | No | 4 |
| M/71 | Gastrointestinal | Rivaroxaban 20 mg | No | 58 | NA | No | 2 |
| M/60 | Hemoglobin fall | Rivaroxaban 20 mg | No | 30 | 205 | No | 1 |
| F/74 | Gastrointestinal | Rivaroxaban 20 mg | No | 26 | NA | No | 2 |
| No major clinically relevant bleeding | |||||||
| F/82 | Vaginal | Apixaban 2.5 mg/BID | No | 134 | 276 | No | 4 |
| F/88 | Intramuscular | Apixaban 2.5 mg/BID | Yes | 127 | NA | No | 3 |
| F/85 | Gastrointestinal | Apixaban 2.5 mg/BID | No | 84 | 186 | No | 3 |
| M/74 | Gastrointestinal | Apixaban 5 mg/BID | No | 72 | 154 | No | 3 |
| M/81 | Hematuria | Apixaban 5 mg/BID | No | 43 | 92 | No | 2 |
| M/71 | Intramuscular | Dabigatran 150 mg/BID | No | 136 | 200 | No | 2 |
| M/79 | Epistaxis | Dabigatran 150 mg/BID | No | 46 | 95 | No | 3 |
| F/79 | Epistaxis | Edoxaban 30 mg | No | 52 | 250 | No | 3 |
| M/75 | Epistaxis | Edoxaban 30 mg | No | 42 | 259 | No | 3 |
| F/89 | Intramuscular | Edoxaban 30 mg | No | 39 | 154 | No | 3 |
| M/77 | Epistaxis | Edoxaban 30 mg | No | 28 | 109 | No | 3 |
| M/86 | Epistaxis | Edoxaban 30 mg | No | 26 | 98 | No | 4 |
| F/80 | Gastrointestinal | Edoxaban 30 mg | No | 19 | 217 | No | 4 |
| F/84 | Epistaxis | Edoxaban 30 mg | Yes | 18 | 188 | No | 4 |
| F/75 | Gengivorrhagia | Edoxaban 30 mg | No | 17 | 277 | No | 3 |
| F/83 | Gastrointestinal | Edoxaban 60 mg | No | 131 | NA | No | 2 |
| M/84 | Epistaxis | Edoxaban 60 mg | No | 39 | 192 | No | 2 |
| M/69 | Intramuscular | Edoxaban 60 mg | No | 21 | 245 | No | 2 |
| M/81 | Hematuria | Rivaroxaban 20 mg | No | 28 | NA | No | 2 |
| F/90 | Vaginal | Rivaroxaban 20 mg | Yes | 25 | NA | No | 3 |
BID, twice a day; F, female; M, male; NA, not available.